Company / Net Income
Aligos Therapeutics, Inc. Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$24.2M
FY2025
5-year range
-$131.2M / -$24.2M
FY2021-FY2025
Trend
+81.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 6 years, ranging from -$131M in FY2024 to -$24M in FY2025.
Based on SEC 10-K filings.
-$24M in FY2025.
Improved from -$96M to -$24M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 81.6% year-over-year.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$24.2M | +81.6% |
| FY2024 | -$131.2M | -36.6% |
| FY2023 | -$96.0M | +25.2% |
| FY2022 | -$128.3M | -18.2% |
| FY2021 | -$108.5M | -107.7% |
| FY2020 | -$52.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026